Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fol...
Bright Minds Biosciences Inc.
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on ...
Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechn...
Detroit Decriminalizes Psychedelics Detroit is the latest to join the growing list of U.S. cities that have decriminalized psy...
Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments. ...
Palo Santo, a newly-created venture capital fund with an eye on psychedelic medicines, announced its official launch on Thursday.
